The ubiquitin-like modifier FAT10 in cancer development |
| |
Affiliation: | 1. LA BioMed at Harbor UCLA Medical Center, Department of Pathology, Torrance, CA 90509, USA;2. VA Medical Center, Department of Medicine, Long Beach, CA, USA;1. Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA;2. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68105, USA;3. Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA;4. Department of Pharmacology and Experimental Neuroscience, Omaha, NE 68105, USA |
| |
Abstract: | During the last years it has emerged that the ubiquitin-like modifier FAT10 is directly involved in cancer development. FAT10 expression is highly up-regulated by pro-inflammatory cytokines IFN-γ and TNF-α in all cell types and tissues and it was also found to be up-regulated in many cancer types such as glioma, colorectal, liver or gastric cancer. While pro-inflammatory cytokines within the tumor microenvironment probably contribute to FAT10 overexpression, an increasing body of evidence argues that pro-malignant capacities of FAT10 itself largely underlie its broad and intense overexpression in tumor tissues. FAT10 thereby regulates pathways involved in cancer development such as the NF-κB- or Wnt-signaling. Moreover, FAT10 directly interacts with and influences downstream targets such as MAD2, p53 or β-catenin, leading to enhanced survival, proliferation, invasion and metastasis formation of cancer cells but also of non-malignant cells. In this review we will provide an overview of the regulation of FAT10 expression as well as its function in carcinogenesis. |
| |
Keywords: | FAT10 UBD Inflammation Ubiquitin proteasome system Carcinogenesis |
本文献已被 ScienceDirect 等数据库收录! |
|